Tango Therapeutics, Inc. (TNGX) Misses Q4 EPS by 5c

Tango Therapeutics, Inc. (NASDAQ: TNGX) reported Q4 EPS of ($0.32), $0.05 worse than the analyst estimate of ($0.27). Revenue for the quarter came in at $5.43 million versus the consensus estimate of $8.62 million.

For earnings history and earnings-related data on Tango Therapeutics, Inc. (TNGX) click here.

You May Also Be Interested In

• Paychex (PAYX) Tops Q1 EPS by 2c
• KB Home (KBH) PT Lowered to $50 at RBC Capital
• KB Home (KBH) Tops Q3 EPS by 16c